Tesofensine Research: Phase 2 Obesity Data and Evidence Review#

The tesofensine clinical evidence base for obesity is anchored by a single 24-week Phase 2 randomised controlled trial published in The Lancet in 2008 (Astrup et al.; PMID 18950853)¹, supplemented by a contemporaneous narrative review (Bello & Zahner, Curr Opin Investig Drugs 2009; PMID 19777399)² and a series of company-disclosed Tesomet program updates from Saniona that have not, as of June 2026, been comprehensively published in peer-reviewed indexed journals³.

Research Overview#

The Astrup 2008 trial is the pivotal published efficacy study¹. In a 24-week dose-ranging design, tesofensine produced a clear dose-response on body weight, with the 1.0 mg group losing approximately 12.8% of total body weight - a magnitude that, at the time, exceeded any then-approved obesity drug. The trial was conducted on a background of hypocaloric diet, was placebo-controlled and double-blind, and enrolled 203 adults with obesity at five Danish sites.

Earlier in tesofensine's development, multiple Phase 2 programs were conducted for Parkinson's disease and Alzheimer's disease in the late 1990s and early 2000s. None met primary efficacy endpoints for neurological symptoms, and CNS development was halted². The unexpected weight-loss signal observed during these trials motivated the redirect into obesity that yielded the 2008 Astrup results.

Saniona subsequently acquired the program and has focused on the combination product Tesomet (tesofensine + metoprolol), with the beta-blocker added to mitigate tesofensine's heart-rate effects³. Tesomet has been studied in:

• General obesity (TIPO-1 and follow-on programs)
• Hypothalamic obesity (rare endocrine condition with severe hyperphagia)
• Prader-Willi syndrome (genetic obesity syndrome)

Topline results have been disclosed by Saniona via press releases and conference presentations, but a peer-reviewed Phase 3 trial publication for Tesomet in general obesity was not yet indexed in PubMed under verifiable identifiers as of June 2026.

Key Studies#

Astrup et al. (2008) - Phase 2 Obesity, The Lancet#

Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9653):1906-1913. PMID: 18950853. DOI: 10.1016/S0140-6736(08)61525-1¹.

• Design: 24-week, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging Phase 2 trial
• Population: 203 adults with obesity at 5 Danish sites
• Intervention: Placebo or tesofensine 0.25 mg, 0.5 mg, or 1.0 mg once daily, on a hypocaloric diet
• Primary endpoint: Mean percentage change in body weight at 24 weeks
• Key results:
  • 1.0 mg: approximately 12.8% total body weight loss; approximately 10.6% placebo-subtracted
  • 0.5 mg: approximately 9.2% placebo-subtracted
  • 0.25 mg: approximately 4.5% placebo-subtracted
• Safety: Dry mouth, nausea, constipation, hard stools, diarrhoea, and insomnia were most common; mean heart-rate increase of approximately 7-8 bpm at higher doses
• Limitations: 24-week duration; single-country population; no active comparator; pre-dates current standard of care

Bello & Zahner (2009) - Review, Current Opinion in Investigational Drugs#

Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Current Opinion in Investigational Drugs. 2009;10(10):1105-1116. PMID: 19777399².

• Narrative review summarizing tesofensine's pharmacology, the failed Parkinson's/Alzheimer's programs, and the Astrup 2008 obesity data
• Documents the terminal half-life of approximately 220 hours and the SERT/NET/DAT triple-inhibition profile
• Identifies sympathomimetic effects on heart rate and blood pressure as the principal safety concern

Saniona Tesomet Program (Ongoing)#

Saniona has reported topline results for several Tesomet trials in obesity, hypothalamic obesity, and Prader-Willi syndrome, including the TIPO-1 obesity trial and dedicated rare-disease programs³. Reported observations across these disclosures include:

• Heart-rate increase is blunted but not eliminated by the metoprolol component
• Weight-loss magnitude in obesity is broadly consistent with the Astrup 2008 data
• Tolerability in rare-disease populations has been a focus, given baseline cardiovascular comorbidity

Because the underlying patient-level data for these trials are not yet broadly available in peer-reviewed indexed publications, this directory does not quote specific percentages from Tesomet trials. Readers should consult Saniona's investor disclosures and ClinicalTrials.gov entries for the most current results.

Evidence Quality Assessment#

Overall evidence level: moderate (downgraded from what the Phase 2 weight-loss magnitude would otherwise suggest, because of the age of the data, single-country sample, and absence of published Phase 3 outcomes).

Research Gaps#

• Peer-reviewed Phase 3 obesity outcomes for tesofensine or Tesomet - the most important gap
• Long-term (more than 2 years) cardiovascular safety in a sympathomimetic-active obesity drug
• Direct comparisons with semaglutide, tirzepatide, and retatrutide
• Combination data with GLP-1 agonists (mechanistically non-overlapping; clinically untested)
• Population-specific data: older adults, those with cardiovascular disease, those with mood disorders
• Real-world abuse-liability data - relevant for any monoamine reuptake inhibitor, particularly DAT-active compounds

References#

Related Reading#

• Tesofensine overview
• Tesofensine dosing
• Tesofensine side effects
• Tesofensine risks and legal status
• Semaglutide research
• Retatrutide research

Footnotes#

1. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9653):1906-1913. PMID: 18950853. DOI: 10.1016/S0140-6736(08)61525-1. ↩ ↩² ↩³ ↩⁴

2. Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Current Opinion in Investigational Drugs. 2009;10(10):1105-1116. PMID: 19777399. ↩ ↩² ↩³

3. Saniona AB. Tesofensine / Tesomet pipeline. https://saniona.com/pipeline/tesofensine. Accessed June 2026. ↩ ↩² ↩³